This is an individualized decision weighing the benefits and potential toxicity. We know from many prospective trials that none of the clinical features mentioned sufficiently put the recurrence risk low enough (often defined as <10%) to omit radiation. However, radiation also likely will not hav...

There is no prospective data on boost for DCIS - we are awaiting the results of the TROG 07.01 trial (2x2 factorial design) looking at standard- vs hypo-fractionation, and boost vs no boost.  Will be presented at SABCS 12/20!  Therefore, it is up to the clinician to decide if tumor factor...